RecruitingNot applicableNCT02592291
Respiratory
Bronchiolitis Obliterans Syndrome
Also known as BOS, constrictive bronchiolitis, post-transplant BO
Bronchiolitis obliterans syndrome is a progressive fibro-obliterative disorder of the small airways that represents the major form of chronic lung allograft dysfunction following lung or haematopoietic stem cell transplantation. It is chara
ORPHA:1303 ↗Prevalence Affects approximately 50% of lung transplant recipients by 5 years post-transplantOnset Post-transplant or post-injury (any age)
97
studies recruiting now
as of 7 Sept 2026
778
studies registered in total
as of 7 Sept 2026
13
countries with a recruiting site
as of 7 Sept 2026
21 Jan 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT07354074
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
RecruitingNCT00128973
Evaluation of Patients With Immune Function Abnormalities
RecruitingNot applicableNCT05685628
Evaluation of the Quality of Life Induced by the Cinnamon Anti-odor Dressing in Patients With Malodorous Wounds
RecruitingPhase 1NCT07127926
Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 97 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Bronchiolitis Obliterans Syndrome study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
About Bronchiolitis Obliterans Syndrome
Bronchiolitis obliterans syndrome is a progressive fibro-obliterative disorder of the small airways that represents the major form of chronic lung allograft dysfunction following lung or haematopoietic stem cell transplantation. It is characterised by concentric fibrosis of bronchiolar walls leading to airflow obstruction that is not fully reversible with bronchodilators. Non-transplant causes include toxic fume inhalation, connective tissue disease, and autoimmune conditions, but the post-transplant form is most prevalent and studied.
Common clinical features
Progressive airflow obstruction (declining FEV1)Dyspnoea on exertionDry coughReduced exercise toleranceRecurrent respiratory infectionsAir trapping on CT imagingAbsence of acute rejection features
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
12 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Cyclosporine (Capimune)
Phase 3Azithromycin (Azasite)
Phase 3Clarithromycin (Biaxin)
Phase 2/3Pirfenidone (Esbriet)
Phase 2Ruxolitinib (Jakavi)
Phase 2Budesonide (Aircort)
Phase 2Bortezomib
Phase 2Nintedanib (Nintedanib component of ofev)
+ 4 more in development
Before you apply
Things trial teams commonly ask about for Bronchiolitis Obliterans Syndrome. Not eligibility rules; those are set by each study.
- BOS is staged by percentage decline in FEV1 from post-transplant baseline (BOS 0-3); confirm your current BOS stage as trials often specify eligible stages.
- Active acute rejection or concurrent infection usually disqualifies patients; ensure these are resolved and documented before applying.
- Time since transplant and immunosuppression regimen are common eligibility variables; have your transplant centre provide a detailed medication history.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).